	Outsourcing of all phases of pharmaceutical/biological development and manufacturing continues to rise. As drug development pipelines shift toward those requiring more complex and specialized capabilities, quality agreements and communication planning to avoid non-compliance and the costly ramifications are becoming more important. This webcast will review the FDA draft guidance document 

Contract Manufacturing Arrangements for Drugs: Quality Agreements

 and provide insights from the contract manufacturing organization (CMO) perspective into the integrated responsibilities and relationship of the contract provider and the drug sponsor.

 for our free, live webinar, “Trends in Quality Agreements & Communications: A CMO Perspective”, to be held on Tuesday, June 23, 2015 at 11 a.m. ET. The presentation will be given by 

Milton Boyer, AMRI’s Senior Vice President of Drug Product Manufacturing.

		Review FDA’s draft guidance document on 

 and the key takeaways about the high cost of non-compliance and lack of quality agreements.
		 

		Understand how heightened enforcement actions changing the traditional relationship between the CMO and drug sponsor.
		 

		Learn how strong CMO partners can help their pharmaceutical/biotechnology partners avoid delays to market, specifically for drug development pipelines requiring more complex and specialized CMO capabilities (e.g., biologics, biosimilars, cytotoxics). 
		 

Register for AMRI’s free, live webinar, entitled “Trends in Quality Agreements & Communications: A CMO Perspective”, which will be held on Tuesday, June 23, 2015 at 11 a.m. ET